Get Live Data

Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally
Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globallyView Video

Latest Share Chat

  2. Share Prices
  3. Glaxosmithkline Share Price
  4. Glaxosmithkline Share News
  5. UK BROKER RATINGS SUMMARY: Peel Hunt Initiates Whitbread With Buy

Pin to quick picksGlaxosmithkline Share News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,594.50
Ask: 1,595.50
Change: -19.00 (-1.17%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS SUMMARY: Peel Hunt Initiates Whitbread With Buy

Mon, 04th Nov 2019 09:10

(Alliance News) - The following London-listed shares received analyst recommendations on Monday morning and Friday afternoon:

----------

FTSE 100

----------

PEEL HUNT INITIATES WHITBREAD WITH 'BUY' - TARGET 4800 PENCE

----------

UBS CUTS SAGE GROUP PRICE TARGET TO 620 (625) PENCE - 'SELL'

----------

UBS RAISES STANDARD CHARTERED PRICE TARGET TO 690 (650) PENCE - 'NEUTRAL'

----------

UBS CUTS LLOYDS PRICE TARGET TO 62 (65) PENCE - 'BUY'

----------

JPMORGAN CUTS LLOYDS PRICE TARGET TO 68 (72) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS SMITH & NEPHEW PRICE TARGET TO 1711 (1814) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS EVRAZ PRICE TARGET TO 375 (400) PENCE - 'UNDERWEIGHT'

----------

LIBERUM RAISES GLAXOSMITHKLINE PRICE TARGET TO 1890 (1510) PENCE - 'HOLD'

----------

DEUTSCHE BANK CUTS VODAFONE PRICE TARGET TO 240 (250) PENCE - 'BUY'

----------

DEUTSCHE BANK CUTS RSA INSURANCE PRICE TARGET TO 560 (565) PENCE - 'HOLD'

----------

DEUTSCHE BANK RAISES INTERNATIONAL CONSOLIDATED AIRLINES PRICE TARGET TO 670 (630) PENCE - 'BUY'

----------

GOLDMAN CUTS EXPERIAN PRICE TARGET TO 2500 (2600) PENCE - 'NEUTRAL'

----------

JEFFERIES CUTS IMPERIAL BRANDS PRICE TARGET TO 2400 (3800) PENCE - 'BUY'

----------

JEFFERIES CUTS BRITISH AMERICAN TOBACCO PRICE TARGET TO 4800 (4900) PENCE - 'BUY'

----------

CREDIT SUISSE CUTS RECKITT-BENCKISER-PRICE TARGET TO 5550 (5800) PENCE - UNDERPERFORM

----------

CREDIT SUISSE CUTS SMITH & NEPHEW PRICE TARGET TO 1725 (1770) PENCE - 'NEUTRAL'

----------

FTSE 250

----------

LIBERUM RAISES PETS AT HOME TO 'BUY' ('HOLD')

----------

UBS CUTS ELEMENTIS PRICE TARGET TO 175 (185) PENCE - 'BUY'

----------

DEUTSCHE BANK RAISES CAPITA GROUP PRICE TARGET TO 140 (120) PENCE - 'HOLD'

----------

BARCLAYS RAISES WORKSPACE GROUP PRICE TARGET TO 1000 (980) PENCE - 'OVERWEIGHT'

----------

BARCLAYS RAISES DERWENT LONDON PRICE TARGET TO 3100 (3000) PENCE - 'UNDERWEIGHT'

----------

BARCLAYS CUTS BBA AVIATION PRICE TARGET TO 347 (350) PENCE - 'OVERWEIGHT'

----------

BERENBERG RAISES FUTURE PRICE TARGET TO 1755 (1530) PENCE - 'BUY'

----------

BERENBERG CUTS MAN GROUP PRICE TARGET TO 192 (206) PENCE - 'BUY'

----------

BERENBERG CUTS BOVIS HOMES PRICE TARGET TO 1220 (1230) PENCE - 'BUY'

----------

JPMORGAN RAISES TRAVIS PERKINS PRICE TARGET TO 1400 (1356) PENCE - 'NEUTRAL'

----------

JEFFERIES CUTS WEIR GROUP PRICE TARGET TO 1395 (1440) PENCE - 'HOLD'

----------

OTHER MAIN MARKET AND AIM

----------

LIBERUM CUTS LOOKERS TO 'HOLD' ('BUY') - TARGET 30 (68) PENCE

----------

BERENBERG RAISES CHEMRING GROUP PRICE TARGET TO 200 (190) PENCE - 'HOLD

----------

BERENBERG RAISES TEAM17 PRICE TARGET TO 375 (330) PENCE - 'BUY'

----------

JPMORGAN CUTS FEVERTREE DRINKS PRICE TARGET TO 2400 (2740) PENCE - 'OVERWEIGHT'

----------

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
20 Jun 2023 08:33

Lab crunch: British science has nowhere to go

OXFORD, England, June 20 (Reuters) - For Ros Deegan, the thrill of raising $100 million to expand a biotech firm among the dreaming spires of Oxford was soon tempered: unable to find a bigger laboratory, she routinely had to work at home.

Read more
16 Jun 2023 17:01

LONDON MARKET CLOSE: FTSE 100 ends a week of rate decisions higher

(Alliance News) - Stocks in London ended largely higher on Friday, following a busy week centred on the interest rate decisions of three major central banks.

Read more
16 Jun 2023 11:59

GSK cancer drug delay by FDA not "necessarily a red flag"

(Alliance News) - GSK PLC must gain approval for its "centrepiece" cancer drug momelotinib to validate its mergers & acquisitions pipeline but the extension of its review period in the US does not automatically spell trouble, according to analysis from Shore Capital on Friday.

Read more
16 Jun 2023 07:47

FDA extends review period of GSK blood cancer drug momelotinib

(Sharecast News) - GSK said on Friday that the US Food and Drug Administration has extended the review period of its new drug application for momelotinib, which is used to treat a blood cancer called myelofibrosis.

Read more
16 Jun 2023 07:42

IN BRIEF: GSK says FDA extending review period for blood cancer drug

GSK PLC - Brentford, England-based pharmaceutical company - Says US Food & Drug Administration has extended the review period of the new drug application for momelotinib by three months. Extension aims to provide time to review recently submitted data. The extended action date is September 16. Momelotinib uses "novel mechanism of action" to treat myelofibrosis, a rare blood cancer, as well as progressive anaemia which characterises the disease. Myelofibrosis affects approximately 25,000 US patients. The drug is not currently approved in any markets. GSK says it is "confident in the momelotinib NDA and looks forward to working with the FDA as they finalise their review."

Read more
9 Jun 2023 06:53

AstraZeneca hails RSV drug nirsevimab recommendation by FDA committee

(Alliance News) - AstraZeneca PLC on Thursday said that a US Food & Drug Administration committee unanimously recommended its antibody nirsevimab.

Read more
8 Jun 2023 12:09

London "still attractive" place to list, as IPO activity trickles back

(Alliance News) - A recent revival of initial public offerings in London's equity markets is encouraging evidence that the city still holds appeal on the global stage, analysts contended.

Read more
7 Jun 2023 09:22

EU approves its first vaccine for common respiratory virus RSV

June 7 (Reuters) - European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually.

Read more
7 Jun 2023 09:10

LONDON MARKET OPEN: Stocks head lower amid global growth fears

(Alliance News) - Stock prices in London opened in the red on Wednesday, as concerns about interest rate hikes and a global economic slowdown damped risk appetite.

Read more
7 Jun 2023 07:59

TOP NEWS: GSK's Arexvy is first EU-approved RSV jab for older adults

(Alliance News) - GSK PLC on Wednesday announced that its RSV vaccine Arexvy has become the first EU-backed vaccine against the respiratory syncytial virus for adults aged 60 and older.

Read more
7 Jun 2023 07:34

GSK gets European approval for RSV vaccine

(Sharecast News) - Pharmaceuticals giant GSK announced on Wednesday that the European Commission has granted authorisation for 'Arexvy' - an adjuvant respiratory syncytial virus (RSV) vaccine - for active immunisation to prevent RSV-caused lower respiratory tract disease (LRTD) in adults 60 and older.

Read more
6 Jun 2023 08:34

US FDA accepts GSK's licence application for cancer treatment Jemperli

(Alliance News) - GSK PLC on Tuesday said the US Food & Drug Administration accepted its supplemental biologics licence application for endometrial cancer treatment dostarlimab, or Jemperli, after it was granted priority review in September.

Read more
6 Jun 2023 07:41

PRESS: Unilever starts search to replace Nils Andersen as chair

(Alliance News) - Unilever PLC has appointed executive search firm Spencer Stuart to find a replacement for Chair Nils Andersen, Bloomberg reported on Monday, citing "people familiar with the situation".

Read more
6 Jun 2023 07:18

US FDA accepts GSK supplemental application for Jemperli cancer drug

(Sharecast News) - GSK said the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application for its Jemperli treatment of adults with primary advanced or recurrent endometrial cancer.

Read more
2 Jun 2023 21:42

IN THE KNOW: hVIVO involvement in drug approval should boost interest

(Alliance News) - hVIVO's involvement in the approval of pharmaceutical giant Pfizer's new vaccine Abrysvo should support interest in its services, according to Liberum.

Read more
181920212223242526

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.